Loading...
Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation
Chronic graft-versus-host disease (cGVHD) is major cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). Ixazomib is an oral, second-generation, proteasome inhibitor (PI) that has been shown in preclinical models to prevent GVHD. We conducted a phase I/II tr...
Na minha lista:
| Udgivet i: | Biol Blood Marrow Transplant |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7571859/ https://ncbi.nlm.nih.gov/pubmed/32653622 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2020.07.005 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|